367
Participants
Start Date
April 30, 2013
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
Tapentadol Prolonged Release
All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
Oxycodone/Naloxone Prolonged Release
All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
AT002, Vienna
AT001, Senftenberg
DE007, Berlin
DE021, Berlin
DE009, Berlin
DE030, Berlin
ES006, A Coruña
DE005, Bad Saarow
ES005, Santiago de Compostela
IT001, Genova
ES008, Guadix
DE025, Schwerin
DE031, Hamburg
IT005, Varese
DE001, Kiel
DE027, Kiel
DE014, Kiel
DE024, Westerstede
IT004, Pavia
ES002, Madrid
ES010, Madrid
ES009, Madrid
DE013, Hanover
ES004, Oviedo
DE015, Magdeburg
IT002, Parma
DE020, Bochum
DE032, Essen
DE029, Cologne
DE008, Cologne
DE006, Mainz
DE017, Frankfurt
DE003, Frankfurt
DE026, Wiesbaden
DE022, Wiesbaden
DE016, Weinheim
IT003, Catania
DE023, Böhlen
DE028, Cottbus
DE012, Dresden
DE011, Görlitz
DE004, Leipzig
DE034, Leipzig
DE018, Leipzig
DE002, Mittweida
DE010, Rudolstadt
DE019, Stadtroda
ES007, Barcelona
ES001, Barcelona
ES003, Centelles
Lead Sponsor
Grünenthal GmbH
INDUSTRY